FDA
-
-
-
-
-
-
-
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
-
-
-
-
-
-
-
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
-
-
-
-
-
-
-
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
-
-
-
-
-
-
-
Ceres (CERE) Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
-
-
-
-
-
-
-
Ceres (CERE) Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
-
-
-
-
-
-
-
Cerevel Therapeutics to Host Inaugural Virtual R&D Event
-
-
-
322,897 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

